Pleiotropic effects of heterozygosity for the SERPINA1 Z allele in the UK Biobank - Fawcett, Katherine A; Song, Kijoung; Qian, Guoqing; Farmaki, Aliki-Eleni; Packer, Richard; John, Catherine; Shrine, Nick; Granell, Raquel; Ring, Sue; Timpson, Nicholas J; Yerges-Armstrong, Laura M; Eastell, Richard; et al. (medRxiv, 2020)
Homozygosity for the SERPINA1 Z allele causes alpha-1 antitrypsin deficiency, a rare condition that can cause lung and liver disease. However, the effects of Z allele heterozygosity on non-respiratory phenotypes, and on lung function in the general population, remain unclear. We conducted the largest population-based study to date to determine Z allele effects on >2,400 phenotypes using the UK Biobank study (N>303,353). We detected strong associations between heterozygosity and non-respiratory phenotypes including increased height, increased risk of gall bladder disease, reduced risk of heart disease and lower blood pressure, reduced risk of osteoarthritis and reduced bone mineral density, increased risk of headache and enlarged prostate, as well as with blood biomarkers of liver function. Heterozygosity was associated with higher lung function in non-smokers, but smoking appears to abolish this protective effect. Individuals heterozygous for the Z allele may therefore have altered risk of smoking-induced lung disease and other, non-respiratory conditions.Competing Interest StatementI.P.H. has received support from GSK, Boehringer Ingelheim and Orion. M.D.T. has received grant support from GSK. L.V.W. has received grant support from GSK. R.A.S. is an employee and shareholder in GSK. L.M.Y. is an employee of GSK and may own company shares. K.S. is an employee of GSK and may own company shares. R.E. receives consultancy funding from IDS, Sandoz, Nittobo, Samsung, Haoma Medica, CL Bio, Biocon and Viking and grant funding from Nittobo, Roche, and Alexion.Funding StatementThe data for this study were partially generated by Medical Research Council (MRC) strategic award to M.D.T., I.P.H., and L.V.W. (MC_PC_12010). The research was partially supported by the NIHR Nottingham Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. M.D.T. is supported by a Wellcome Trust Investigator Award (WT202849/Z/16/Z). M.D.T. and L.V.W. have been supported by the MRC (MR/N011317/1). The research was partially supported by the NIHR Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. L.V.W. holds a GSK/British Lung Foundation Chair in Respiratory Research. K.A.F. holds an Asthma UK fellowship award. I.P.H. holds a NIHR Senior Investigator award. C.J. holds a Medical Research Council Clinical Research Training Fellowship (MR/P00167X/1). We would like to acknowledge the support of the Health Data Research UK BREATHE Digital Innovation Hub funded by URKI (MC_PC_19004). The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for the Avon Longitudinal Study of Parents and Children (ALSPAC). This publication is the work of the authors and Raquel Granell will serve as guarantor for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf. N.J.T. is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of ALSPAC (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC_UU_00011) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A19169).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Details of ethical approvals for UK Biobank and ALSPAC cohorts are provided in the main manuscript and supplementary methods.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the results of this study are available in the main manuscript and supplementary material.